We have located links that may give you full text access.
Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific.
American Journal of Surgery 2019 July
BACKGROUND: We sought to assess participation of underrepresented minorities with endocrine neoplasms in clinical trials conducted in the National Cancer Institute's (NCI) Intramural Research Program.
METHODS: We performed a retrospective analysis of patients enrolled in Endocrine Oncology Branch (EOB) clinical trials, comparing demographics to regional and national demographics. We compared specific endocrine cancer patient data to data from NCI's Surveillance, Epidemiology, and End Results (SEER) program.
RESULTS: Comparing EOB patients to national demographics, we found more white (77% vs 74%, P < 0.001) and black patients (14% vs 12%, P < 0.001). For thyroid cancer, there were more black (16% vs 7%, P < 0.0001) and other minority patients (17% vs 11%, P < 0.0001) compared to SEER. For gastroenteropancreatic neuroendocrine tumors (GEPNETs), there were fewer black (6% vs 19%, P < 0.0001) and other minority patients (6% vs 8%, P < 0.0001).
CONCLUSION: Enrollment parity of underrepresented minorities into clinical trials is achievable, although possibly cancer type-specific.
METHODS: We performed a retrospective analysis of patients enrolled in Endocrine Oncology Branch (EOB) clinical trials, comparing demographics to regional and national demographics. We compared specific endocrine cancer patient data to data from NCI's Surveillance, Epidemiology, and End Results (SEER) program.
RESULTS: Comparing EOB patients to national demographics, we found more white (77% vs 74%, P < 0.001) and black patients (14% vs 12%, P < 0.001). For thyroid cancer, there were more black (16% vs 7%, P < 0.0001) and other minority patients (17% vs 11%, P < 0.0001) compared to SEER. For gastroenteropancreatic neuroendocrine tumors (GEPNETs), there were fewer black (6% vs 19%, P < 0.0001) and other minority patients (6% vs 8%, P < 0.0001).
CONCLUSION: Enrollment parity of underrepresented minorities into clinical trials is achievable, although possibly cancer type-specific.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app